Brief: Collaborative Study With Melanoma Research Foundation Confirms Patients Diagnosed With Melanoma Desire Testing With Decisiondx-Melanoma
14/06/2022 12:29
June 14 (Reuters) -
* COLLABORATIVE STUDY WITH MELANOMA RESEARCH FOUNDATION
CONFIRMS
PATIENTS DIAGNOSED WITH MELANOMA DESIRE TESTING WITH
DECISIONDX®-MELANOMA
Source text for Eikon: ID:nBwb0q5mLa
Further company coverage: CSTL.O
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million